Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100


Novel functional assay for spindle-assembly checkpoint by cyclin-dependent kinase activity to predict taxane chemosensitivity in breast tumor patient.

Torikoshi Y, Gohda K, Davis ML, Symmans WF, Pusztai L, Kazansky A, Nakayama S, Yoshida T, Matsushima T, Hortobagyi GN, Ishihara H, Kim SJ, Noguchi S, Ueno NT.

J Cancer. 2013 Nov 14;4(9):697-702. doi: 10.7150/jca.6248. eCollection 2013.


Cyclin G1 regulates the outcome of taxane-induced mitotic checkpoint arrest.

Russell P, Hennessy BT, Li J, Carey MS, Bast RC, Freeman T, Venkitaraman AR.

Oncogene. 2012 May 10;31(19):2450-60. doi: 10.1038/onc.2011.431. Epub 2011 Nov 7.


PRP4K is a HER2-regulated modifier of taxane sensitivity.

Corkery DP, Le Page C, Meunier L, Provencher D, Mes-Masson AM, Dellaire G.

Cell Cycle. 2015;14(7):1059-69. doi: 10.1080/15384101.2015.1007775.


Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.

Ward S, Simpson E, Davis S, Hind D, Rees A, Wilkinson A.

Health Technol Assess. 2007 Oct;11(40):1-144. Review.


Prediction of paclitaxel sensitivity by CDK1 and CDK2 activity in human breast cancer cells.

Nakayama S, Torikoshi Y, Takahashi T, Yoshida T, Sudo T, Matsushima T, Kawasaki Y, Katayama A, Gohda K, Hortobagyi GN, Noguchi S, Sakai T, Ishihara H, Ueno NT.

Breast Cancer Res. 2009;11(1):R12. doi: 10.1186/bcr2231. Epub 2009 Feb 24.


Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies.

Murray S, Briasoulis E, Linardou H, Bafaloukos D, Papadimitriou C.

Cancer Treat Rev. 2012 Nov;38(7):890-903. doi: 10.1016/j.ctrv.2012.02.011. Epub 2012 Mar 31. Review.


Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer.

Van Poznak C, Tan L, Panageas KS, Arroyo CD, Hudis C, Norton L, Seidman AD.

J Clin Oncol. 2002 May 1;20(9):2319-26.


Cyclin A-associated kinase activity is needed for paclitaxel sensitivity.

Takahashi T, Yamasaki F, Sudo T, Itamochi H, Adachi S, Tamamori-Adachi M, Ueno NT.

Mol Cancer Ther. 2005 Jul;4(7):1039-46.


The Fcp1-Wee1-Cdk1 axis affects spindle assembly checkpoint robustness and sensitivity to antimicrotubule cancer drugs.

Visconti R, Della Monica R, Palazzo L, D'Alessio F, Raia M, Improta S, Villa MR, Del Vecchio L, Grieco D.

Cell Death Differ. 2015 Sep;22(9):1551-60. doi: 10.1038/cdd.2015.13. Epub 2015 Mar 6.


A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer.

Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, Vidaurre T, Holmes F, Souchon E, Wang H, Martin M, Cotrina J, Gomez H, Hubbard R, Chacón JI, Ferrer-Lozano J, Dyer R, Buxton M, Gong Y, Wu Y, Ibrahim N, Andreopoulou E, Ueno NT, Hunt K, Yang W, Nazario A, DeMichele A, O'Shaughnessy J, Hortobagyi GN, Symmans WF.

JAMA. 2011 May 11;305(18):1873-81. doi: 10.1001/jama.2011.593.


USP7 and Daxx regulate mitosis progression and taxane sensitivity by affecting stability of Aurora-A kinase.

Giovinazzi S, Morozov VM, Summers MK, Reinhold WC, Ishov AM.

Cell Death Differ. 2013 May;20(5):721-31. doi: 10.1038/cdd.2012.169. Epub 2013 Jan 25.


Taxane-containing regimens for metastatic breast cancer.

Ghersi D, Willson ML, Chan MM, Simes J, Donoghue E, Wilcken N.

Cochrane Database Syst Rev. 2015 Jun 10;(6):CD003366. doi: 10.1002/14651858.CD003366.pub3. Review.


Specific kinesin expression profiles associated with taxane resistance in basal-like breast cancer.

Tan MH, De S, Bebek G, Orloff MS, Wesolowski R, Downs-Kelly E, Budd GT, Stark GR, Eng C.

Breast Cancer Res Treat. 2012 Feb;131(3):849-58. doi: 10.1007/s10549-011-1500-8. Epub 2011 Apr 9.


Unliganded progesterone receptors attenuate taxane-induced breast cancer cell death by modulating the spindle assembly checkpoint.

Badtke MM, Jambal P, Dye WW, Spillman MA, Post MD, Horwitz KB, Jacobsen BM.

Breast Cancer Res Treat. 2012 Jan;131(1):75-87. doi: 10.1007/s10549-011-1399-0. Epub 2011 Feb 22.


Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers.

Mazouni C, Kau SW, Frye D, Andre F, Kuerer HM, Buchholz TA, Symmans WF, Anderson K, Hess KR, Gonzalez-Angulo AM, Hortobagyi GN, Buzdar AU, Pusztai L.

Ann Oncol. 2007 May;18(5):874-80. Epub 2007 Feb 10.


The spindle checkpoint requires cyclin-dependent kinase activity.

D'Angiolella V, Mari C, Nocera D, Rametti L, Grieco D.

Genes Dev. 2003 Oct 15;17(20):2520-5.


Chemotherapy response assay test and prognosis for breast cancer patients who have undergone anthracycline- and taxane-based chemotherapy.

Lee A, Lim W, Moon BI, Paik NS, Koh SH, Song JY.

J Breast Cancer. 2011 Dec;14(4):283-8. doi: 10.4048/jbc.2011.14.4.283. Epub 2011 Dec 27.


Mad2 and BubR1 modulates tumourigenesis and paclitaxel response in MKN45 gastric cancer cells.

Bargiela-Iparraguirre J, Prado-Marchal L, Pajuelo-Lozano N, Jiménez B, Perona R, Sánchez-Pérez I.

Cell Cycle. 2014;13(22):3590-601. doi: 10.4161/15384101.2014.962952.


BRCAness predicts resistance to taxane-containing regimens in triple negative breast cancer during neoadjuvant chemotherapy.

Akashi-Tanaka S, Watanabe C, Takamaru T, Kuwayama T, Ikeda M, Ohyama H, Mori M, Yoshida R, Hashimoto R, Terumasa S, Enokido K, Hirota Y, Okuyama H, Nakamura S.

Clin Breast Cancer. 2015 Feb;15(1):80-5. doi: 10.1016/j.clbc.2014.08.003. Epub 2014 Sep 28.


Predictive factors of pathologic complete response and clinical tumor progression after preoperative chemotherapy in patients with stage II and III breast cancer.

Jeong JH, Jung SY, Park IH, Lee KS, Kang HS, Kim SW, Kwon Y, Kim EA, Ko KL, Nam BH, Lee S, Ro J.

Invest New Drugs. 2012 Feb;30(1):408-16. doi: 10.1007/s10637-010-9555-7. Epub 2010 Oct 5.


Supplemental Content

Support Center